Study wrapper · #512
Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.
Editor's note
This is a pharmacovigilance (disproportionality) analysis of the FDA Adverse Event Reporting System (FAERS) identifying drugs statistically over-reported alongside carpal tunnel syndrome. Tesamorelin appeared among ten drugs with a strong signal (reporting odds ratio ~20.7). This design detects associations in spontaneous-reporting data — it cannot establish causation, is subject to reporting bias, and lacks a defined denominator of exposed patients. Still, it is directly relevant to our safety coverage: a growth-hormone-axis mechanism is biologically plausible for carpal tunnel syndrome, and this signal warrants clinician awareness rather than alarm. Frame it as a hypothesis-generating safety signal, not evidence that tesamorelin causes carpal tunnel syndrome. Any peptide page should carry side-effect information above the fold.
Plain-language abstract
Researchers searched the FDA's adverse-event database (covering 2003-2024) for medicines that showed up unusually often in reports of carpal tunnel syndrome, a nerve-compression problem in the wrist. Out of nearly 13 million adverse-event reports, about 6,800 involved carpal tunnel syndrome, mostly in women averaging 57 years old. Ten drugs stood out as strongly over-represented, including tesamorelin (a growth-hormone-releasing hormone analog) alongside enzyme-replacement therapies, an aromatase inhibitor, and bone drugs. The authors say clinicians should stay alert for new or worsening carpal tunnel symptoms in patients taking these medicines. Importantly, this type of database study can only flag a statistical association from voluntary reports; it cannot show that a drug caused the condition, and the true rate among people taking each drug is unknown.